Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress

Scandinavian Journal of Rheumatology

Volumn 39, Issue 1, 2010, Pages 63-70

  Hardardottir H ^a   Van Helvoort, H A C ^a   Vonk, M C ^a   Van Den Hoogen, F H J ^a   Dekhuijzen, P N R ^a   Heijdra, Y F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL DERIVATIVE; INTERLEUKIN 6; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ARTICLE; BASAL CELL; BLOOD SAMPLING; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLING; EXERCISE TOLERANCE; FEMALE; GAS EXCHANGE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PHYSIOLOGY; PRIORITY JOURNAL; REST; SCORING SYSTEM; SKIN; SYSTEMIC SCLEROSIS;

ADULT; AGE FACTORS; AGED; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEUKOCYTOSIS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHYSICAL ENDURANCE; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 76749145570     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903124416     Document Type: Article

References (39)

1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;/2:/152-7.
2. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003;/2:/181-91.
3. Kampolis C, Plastrias S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol 2008;/37:/ 278-83.
4. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;/28:/78-85.
5. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford: Oxford University Press; 1999.
6. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;/27:/645-53.
7. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;/ 185:/1371-80.
8. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheumatol Rep 2000;/2:/501-5.
9. Distler O, Rinkes B, Hohenleutner U, Scholmerich J, Landthaler M, Lang B, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999;/19:/39-46.
10. Leroy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989;/32:/817-25.
11. Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999;/79:/207-10.
12. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997;/24:/663-5.
13. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;/138:/540-6.
14. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin- 6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;/27:/140-6.
15. Schwaiblmair M, Behr J, Fruhmann G. Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis. Chest 1996;/110:/1520-5.
16. Van Helvoort HA, van de Pol MH, Heijdra YF, Dekhuijzen PN. Systemic inflammatory response to exhaustive exercise in patients with chronic obstructive pulmonary disease. Respir Med 2005;/99:/1555-67.
17. Valentini S, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;/62:/904-5. (Pubitemid 37026506)
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
19. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77.
20. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;/60:/2020-7.
21. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clin Chem 1991;/37:/1273-5.
22. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;/23:/361-6.
23. Zusterzeel PL, Mulder TP, Peters WH, Wiseman SA, Steegers EA. Plasma protein carbonyls in nonpregnant, healthy pregnant and preeclamptic women. Free Radic Res 2000;/33:/471-6.
24. Wanten GJ, Naber AH, Kruimel JW, Tool AT, Roos D, Jansen JB. Influence of structurally different lipid emulsions on human neutrophil oxygen radical production. Eur J Clin Invest 1999;/29:/357-63.
25. Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 1974;/37:/247-8.
26. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;/ 15:/202-5.
27. Sudduth CD, Strange C, Cook WR, Miller KS, Baumann M, Collop NA, et al. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med 1993;/95:/413-8.
28. Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation, 4th edn. Baltimore: Lippincott Williams & Wilkins; 2005.
29. Alkotob ML, Soltani P, Sheatt MA, Katsetos MC, Rothfield N, Hager WD, et al. Reduced exercise capacity and stressinduced pulmonary hypertension in patients with scleroderma. Chest 2006;/130:/176-81.
30. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;/48:/ 516-22. (Pubitemid 36278021)
31. de Oliveira NC, dos Santos Sabbag LM, Ueno LM, de Souza RB, Borges CL, de Sa Pinto AL, et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007;/36:/458-61.
32. Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev 2000;/80:/1055-81.
33. Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;/ 14:/537-50.
34. Tikly M, Channa K, Theodorou P, Gulumian M. Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 2006;/25:/320-4.
35. Lau CS, O'Dowd A, Belch JJ. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration inducedwhite finger syndrome. Ann Rheum Dis 1992;/51:/249-52.
36. Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford) 2006;/45:/314-20.
37. Musellim B, Ikitimur H, Uzun H, Ongen G. The oxidant- antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 2006;/27:/163-7.
38. Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006;/58:/951-7.
39. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006;/45:/815-8. (Pubitemid 43985368)